Eli Lilly's $44.58 Billion Trading Volume Lands 19th as Stock Drops 11.55% in Three Days

On April 7, 2025, Eli Lilly and Company (LLY) recorded a trading volume of $44.58 billion, ranking 19th in the day's market activity. The stock experienced a decline of 1.96%, marking its third consecutive day of losses, with a cumulative drop of 11.55% over the past three days.

Eli Lilly and Company has announced its expectation for 2024 full-year worldwide revenue to be approximately $45.0 billion, indicating significant growth. This projection comes as the company navigates a challenging market environment, where its stock has sold off alongside broader market trends, undercutting its moving averages.

Recent trading saw Eli Lilly shares fall almost 4% after the Trump administration decided to table a plan allowing Medicare to pay for anti-obesity drugs. This decision has had a notable impact on the company's stock performance, contributing to a 10.6% decline over the past week and marking a 52-week low at $697.35.

Analysts have been actively revising their price targets for Eli Lilly shares. Wells Fargo & Company, among others, has raised its target price, reflecting a mix of optimism and caution in the face of recent market developments. Additionally, Fmr LLC reduced its holdings in Eli Lilly shares by 7.6% in the fourth quarter, indicating a strategic adjustment in investment positions.